{"id":"W3110328268","doi":"10.2340/00015555-3700","title":"An Analysis of Patient-reported Outcomes in IXORA-S: Comparing Ixekizumab and Ustekinumab over 52 Weeks in Moderate-to-severe Psoriasis","year":2020,"lang":"en","type":"article","venue":"Acta Dermato Venereologica","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Samsung; LEO Pharma; Dermira; Sun Pharma; Regeneron Pharmaceuticals; Baxalta; Biogen; Celgene; Mylan; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ixekizumab; Ustekinumab; Medicine; Dermatology Life Quality Index; Psoriasis; Quality of life (healthcare); Dermatology; Psoriasis Area and Severity Index; Physical therapy; Internal medicine; Psoriatic arthritis; Disease; Adalimumab; Nursing; Secukinumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003748906,0.0003511436,0.001068282,0.0003952065,0.0001527287,0.0003936015,0.0002714314,0.0003406032,0.0009961781],"category_scores_gemma":[0.002321455,0.0001247547,0.001349537,0.000346514,0.0002531033,0.0004401625,0.0004012717,0.0006839904,0.0001299015],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002654142,"about_ca_system_score_gemma":0.0002724979,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003187578,"about_ca_topic_score_gemma":0.000400381,"domain_scores_codex":[0.9981108,0.001076667,0.0001522631,0.0001882917,0.0003372883,0.0001346416],"domain_scores_gemma":[0.9977534,0.0008387554,0.0008330806,0.0001711823,0.0001678454,0.000235678],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.4314164,0.01216751,0.3303081,0.00117998,0.006727105,0.0002341654,0.0005599084,0.005547716,0.05065209,0.0002404522,0.0008962333,0.1600703],"study_design_scores_gemma":[0.009681691,0.186107,0.7879899,0.00004852692,0.00189006,0.0003124648,0.000180657,0.004724741,0.007527654,0.00012839,0.001353338,0.00005566106],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.998778,0.0004336042,0.0002200888,0.00001779583,0.000009442401,0.00007190889,0.0001868341,0.000005626428,0.0002767475],"genre_scores_gemma":[0.9989343,0.0001232847,0.0002609284,0.00003058851,0.00001889969,0.0001018727,0.000349197,0.000002226917,0.0001786147],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003748906,"threshold_uncertainty_score":0.01982635,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02543178024048303,"score_gpt":0.2567801333372463,"score_spread":0.2313483530967633,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}